

## PRODUCT KEY FACTS

Janus Henderson Capital Funds plc (the “Company”)  
Janus Henderson Global Life Sciences Fund (the “Fund”)

April 2022

- This document provides you with key information about the Fund.
- This document forms a part of and should be read in conjunction with the Hong Kong Offering Document.
- You should not invest in this product based on this document alone.

### Quick facts

Management Company:	Henderson Management S.A.	
Investment Adviser:	Janus Capital International Limited, a UK company (internal delegation)	
Sub-Investment Adviser:	Janus Henderson Investors US LLC, a US company (internal delegation)	
Depository:	J.P. Morgan SE, Dublin Branch	
Ongoing charges over a year:	Class A2 USD	2.38%#
	Class B2 USD	3.39%#
	Class I2 USD	1.56%#
	Class H2 USD	0.86%#
	Class H1 USD	0.85%#
	Class A2 HEUR	2.38%#
	Class I2 HEUR	1.56%#
	Class H2 EUR	0.85%#
	Class H2 HEUR	0.85%#
	Class A2 HKD	2.37%#
	Class I2 HKD	1.49%*
	Class A2 HAUD	2.39%#
	Class I2 HAUD	1.50%*
	Class A2 HCAD	2.38%^
	Class A2 HNZD	2.38%^
	Class A2 HSGD	2.37%#
	Class H2 GBP	0.86%#
	Class H1 GBP	0.85%#
	Class H2 HGBP	0.86%^
	Class H2 HCHF	0.86%^

#The ongoing charges figure is calculated based on expenses for the financial year ended 31 December 2021 (“Reporting Period”), excluding transactions costs and trade commissions, incurred by the Share Class during the Reporting Period expressed as a percentage of the average net assets for the corresponding period. The figure may vary from year to year.

\*The ongoing charges figure is an annualized figure calculated based on expenses for the period from 14 April 2021 to 31 December 2021 (“**Relevant Period**”), excluding transactions costs and trade commissions, incurred by the Share Class during the Relevant Period expressed as a percentage of the average net assets for the corresponding period. The actual figure may be different upon actual operation of the Share Class and the figure may vary from year to year.

^ The ongoing charges figure for this Share Class is an estimate only as the Share Class is not yet launched. The estimated figure represents the actual ongoing charge for the same period of an equivalent fee structured Share Class, typically in an alternative currency or distribution type. The actual figure may be different upon actual operation of the Share Class and the figure may vary from year to year.

Dealing Frequency: Daily (generally any day on which the New York Stock Exchange is open for business) (“Business Day”)

Base Currency: US Dollar

Minimum Investment:	Share Classes	Initial	Additional
	US Dollar		
	Class A2 USD	US\$2,500	US\$100
	Class B2 USD		
	Class H2 USD	Class H1 USD	
	Class I2 USD	US\$1,000,000	N/A
	Euro		
	Class A2 HEUR	€2,500	€100
	Class H2 EUR		
	Class H2 HEUR		
	Class I2 HEUR	€1,000,000	N/A
	Hong Kong Dollar		
	Class A2 HKD	HK\$15,000	HK\$750
	Class I2 HKD	HK\$8,000,000	N/A
	Australian Dollar		
	Class A2 HAUD	AUD\$2,500	AUD\$100
	Class I2 HAUD	AUD\$1,000,000	N/A
	Canadian Dollar		
	Class A2 HCAD	CAD\$2,500	CAD\$100
	New Zealand Dollar		
	Class A2 HNZD	NZD\$2,500	NZD\$100
	Singapore Dollar		
	Class A2 HSGD	SGD\$2,500	SGD\$100
	Pound Sterling		
	Class H2 GBP	Class H1 GBP	£2,500
	Class H2 HGBP		£100
	Swiss Franc		
	Class H2 HCHF	CHF2,500	CHF100

Please contact the Distributor and/or Hong Kong Representative for further information on Share Classes available to investors.

For each Share Class currency prefixed with “H” in the name of the Share Class, the Sub-Investment Adviser will employ techniques to hedge the Share Class’s exposure to changes in exchange rates between the Base Currency of the Fund and the currency of the Share Class.

**Dividend Policy:**

Share Classes H1 USD and H1 GBP will distribute dividends (if any) annually.

For Series 1 Share Classes, the Company may at its discretion distribute substantially all of the investment income for the relevant accounting period after the deduction of fees, charges and expenses. Distributions will not include realised and unrealised capital gains.

The Fund will not declare or make dividend payments on Series 2 Share Classes.

Financial Year End of the Fund: 31 December

## **What is this product?**

The Fund is a sub-fund of the Company which is constituted in the form of a mutual fund. The Company is domiciled in Ireland and established as an umbrella fund with segregated liability between sub-funds. The Company's home regulator is the Central Bank of Ireland (the "Central Bank").

## **Objective and Investment Strategy**

The Fund's investment objective is to seek long-term growth of capital.

The Fund pursues its objective by investing at least 80% of its net asset value in equities (also known as company shares) located anywhere in the world and selected for their growth potential.

The Fund will invest at least 80% of its net asset value in companies that the relevant Sub-Investment Adviser believes have a life sciences orientation. Generally speaking, the "life sciences" relate to maintaining or improving quality of life. Thus, companies with a "life sciences orientation" include companies engaged in research, development, production or distribution of products or services related to health and personal care, medicine or pharmaceuticals. Such companies may also include companies that the relevant Sub-Investment Adviser believes have growth potential mainly as a result of particular products, technology, patents or other market advantages in the life sciences.

The Fund may invest in financial derivative instruments ("FDI") for investment purposes. The Fund may employ investment techniques and instruments, such as trading in futures, options and swaps and other FDI for efficient portfolio management (i.e. reduction of risk, reduction of costs, generation of additional capital or income for the Fund) or subject to a limit of 10% of its NAV, for investment purposes and subject to the conditions and within the limits from time to time laid down by the Central Bank to gain or hedge exposure to the investments contemplated in the investment policy for the Fund.

The Sub-Investment Adviser may invest in companies of any size, from larger, well-established companies to smaller, emerging growth companies. The Fund may invest in companies located anywhere in the world (including developing markets) but the aggregate amount of the Fund which may be invested in securities traded on the developing markets is 20% of the net asset value of the Fund and no more than 10% of the net asset value of the Fund may be invested in securities traded on any one developing market. The Sub-Investment Adviser typically takes a balanced approach in allocating across sub-sectors which include, but are not limited to, biotechnology, pharmaceuticals, health care services and medical devices.

The Fund seeks to outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The Sub-Investment Adviser has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.

There is no guarantee that the Fund's performance will match or exceed that benchmark. The Sub-Investment Adviser generally takes a "bottom-up" or stock picking approach to building a portfolio of investments which are built one security at a time following in house research into each company. Companies are considered principally on their own fundamental qualitative and quantitative characteristics. The Sub-Investment Adviser

looks to identify innovative healthcare companies addressing high unmet medical needs. The team understands that success of drug development is binary in nature, creating wide disparities between winners and losers. The investment process leverages proprietary statistical models to analyse the probability of a company's success, focusing on products they believe can overcome the rigours of clinical development. Additional tools, such as physician surveys and prescription models, attempt to more accurately predict commercial viability.

The Fund will not invest more than 10% of its net asset value in securities issued or guaranteed by a single country (including its government, a public or local authority of that country) with a credit rating below investment grade.

Under exceptional circumstances (e.g. emergency market conditions), the Fund may not adhere to its investment policies as disclosed, and may temporarily hold up to 100% of its net asset value in cash or invest in money market instruments, short-term debt securities issued or guaranteed by national governments located globally; short-term corporate debt securities including freely transferable promissory notes, debentures, bonds (including zero coupon bonds), convertible and non-convertible notes, commercial paper, certificates of deposits, and bankers acceptances to preserve the value of the Fund or limit losses.

The Fund may engage in securities financing transactions, including securities lending, sale and repurchase and/or reverse repurchase transactions, for up to 50% of its net asset value in aggregate.

## **Use of Derivatives**

The Fund's net derivative exposure may be up to 50% of the Fund's net asset value.

## **What are the key risks?**

Investment involves risks. Please refer to the Hong Kong Offering Document for details including the risk factors.

### **1. General Investment Risk**

There can be no assurance that the Fund will achieve the desired results of its specific investment objective and strategy under all circumstances and market conditions. The net asset value of the Fund may rise or fall, as the capital value of the securities in which the Fund invests may fluctuate. Depending on the distribution policy of a Share Class, the investment income of the relevant Share Class is based on the income earned on the securities the Fund holds, less expenses incurred. Therefore, the relevant Share Class's investment income may be expected to fluctuate in response to changes in such expenses or investment income. The Fund's investment portfolio may fall in value due to any of the key risk factors below and therefore your investment in the Fund may suffer losses. There is no guarantee of the repayment of principal.

### **2. Equity Market Risk**

The Fund's investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors, such as changes in investment sentiment, political and economic conditions and issuer-specific factors.

### **3. Risk Associated with Small-capitalisation/Mid-capitalisation Companies**

- Smaller or newer companies may suffer more significant losses as well as realise more substantial growth than larger or more established issuers due to the fact that these companies may lack depth of management, be unable to generate funds necessary for growth or potential development, or be developing or marketing new products or services for which markets are not yet established and may never be established.
- Such companies may also have more limited trading markets and may be subject to wide price fluctuations. Investments in such companies may have lower liquidity and tend to be more volatile to adverse economic developments and somewhat more speculative than those of larger capitalisation companies in general, and may therefore be more likely to suffer loss which may affect the performance of the Fund.

### **4. Concentration of Investments**

The Fund seeks to maintain a diversified portfolio of investments. However, as the Fund invests primarily in

securities of companies that the relevant Sub-Investment Adviser believes have a life sciences orientation, it may be less diversified in its investments than other funds. As a result, changes in government funding or subsidies, new or anticipated legislative changes, or technological advances could affect the value of such companies. This Fund's returns, therefore, may be more volatile than those of a less concentrated portfolio.

The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments. Increased concentration of investments by the Fund will increase the risk of the Fund suffering proportionately higher loss should a particular investment decline in value or otherwise be adversely affected. The value of the Fund may be more susceptible to adverse economic, political, policy, foreign exchange, liquidity, tax, legal or regulatory event affecting the relevant market.

## 5. Risks associated with securities financing transactions

- Engaging in securities financing transactions leads to credit risk exposure for the Fund. In order to mitigate this exposure, counterparties are required to provide high quality and liquid collateral cover. However, the Fund may still be subject to the risks as described below. Possible events of default by a counterparty, combined with a fall in the value of the collateral below that of the value of the securities subject to the relevant securities financing transaction, may result in a reduction in the net asset value of the Fund.
- *Risks relating to securities lending transactions:* Securities lending transactions may involve the risk that the borrower may fail to return the securities lent out in a timely manner and the value of the collateral may fall below the value of the securities lent out, and the borrower may not provide additional collateral when required.
- *Risks relating to sale and repurchase transactions:* In the event of the failure of the counterparty with which collateral has been placed, the Fund may suffer loss as there may be delays in recovering collateral placed out or the cash originally received may be less than the collateral placed with the counterparty due to inaccurate pricing of the collateral or market movements.
- *Risks relating to reverse repurchase transactions:* In the event of the failure of the counterparty with which cash has been placed, the Fund may suffer loss as there may be delay in recovering cash placed out or difficulty in realising collateral or proceeds from the sale of the collateral may be less than the cash placed with the counterparty due to inaccurate pricing of the collateral or market movements, and the relevant counterparty may not provide additional collateral when required.


## 6. Risk of Investing in FDI

- The Fund may invest in FDI for investment purposes. Given the leverage effect of FDI, such investments may result in a loss significantly greater than the amount invested in the FDI by the Fund. Exposure to FDI may lead to total loss or a high risk of substantial loss by the Fund.
- The price of FDI may move in unexpected ways, especially in abnormal market conditions.
- FDI involve other risks of loss, such as credit, currency, leverage, counterparty, liquidity, index, settlement default, valuation, volatility, over-the-counter transaction and interest risks.
- Increased margin calls and unlimited risk of loss are also risks which may arise through the use of FDI as is the potential inability to terminate or sell FDI positions.

## 7. Currency Risk and Currency Hedging Risk

As long as the Fund holds securities denominated in a currency other than the base currency of the Fund, the Fund's value will be affected by the value of the local currency relative to the base currency. Also, a share class may be designated in a currency other than the base currency of the Fund. The net asset value of the Fund may be affected unfavourably by fluctuations in the exchange rates between these currencies and the base currency and by changes in exchange rate controls. In such instances, the Fund may apply currency hedging techniques, including the use of currency forward contracts, in order to limit the currency exposure between the currencies of the Fund's investment portfolio and the base currency. However, this may not be possible or practicable in all cases.

## How has the Fund performed?



- Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
- The computation basis of the performance is based on the calendar year end, NAV to NAV, with dividend reinvested.
- These figures show by how much the share class increased or decreased in value during the calendar year being shown. Performance data has been calculated in USD, including ongoing charges and excluding subscription fee, switching fee and redemption fee you might have to pay.
- Fund launch date: 31 March 2000.
- Class A2 USD launch date: 31 March 2000.
- The Investment Adviser views Class A2 USD, being the retail share class denominated in the Fund's base currency and available to the public of Hong Kong, as the most appropriate representative share class.
- The past performance information regarding the other share classes (where available) can be obtained through [www.janushenderson.com](http://www.janushenderson.com). This website has not been reviewed by the SFC.

## Is there any guarantee?

The Fund does not have any guarantees. You may not get back the full amount of money you invest.

## What are the fees and charges?

### Charges which may be payable by you

You may have to pay the following fees when dealing in the shares of the Fund.

	Class A	Class B	Class H	Class I
Subscription fee (Initial Sales Charge) (% of the amount subscribed)	Up to 5.00 %	Nil	Nil	Up to 2.00%
Switching fee (Exchange Fee)	Nil	Nil	Nil	Nil
Redemption Fee	Nil	Nil	Nil	Nil
Contingent Deferred Sales Charge (% of the lesser of the net asset value per share at the date of redemption or the original cost of the shares to be redeemed)	Nil	4% (for holding period of less than 1 year) 3% (for holding period of 1 year and above but less than 2 years) 2% (for holding period of 2 years and above but less than 3 years) 1% (for holding period of 3 years and above but less than 4 years) nil (for holding period of 4 years and above)	Nil	Nil

### Ongoing fees payable by the Fund

The following ongoing fees and expenses will be paid out of the Fund. They affect you because they reduce the return you get on your investments.

	Annual Rate (% of the net asset value of each class)			
	Class A	Class B	Class H	Class I
Management Fee The Fund pays to the Management Company	Up to 0.025% of the Fund			
Investment Management Fee The Fund pays to the Investment Adviser	1.5% (current and maximum permitted under the Prospectus for this Fund)	0.80% (current and maximum permitted under the Prospectus for this Fund)	1.5% (current and maximum permitted under the Prospectus for this Fund)	
Depository Fee The Fund pays to the Depository	Included in the "Expenses" below			
Administration Fee The Fund pays to the Administrator	Included in the "Expenses" below			

Performance Fee	Nil			
Shareholder Service Fee The Fund pays to the Distributor	Up to 0.75%	Nil	Nil	
	Annual Rate (% of the net asset value of each class)			
Distribution Fee The Fund pays to the Distributor	Nil	Up to 1%	Nil	Nil
Expenses The Fund pays a fee for administration, accounting, custody services as part of its expenses	Up to 0.75%			Up to 0.25%
Total Fees and Expenses Limit	2.75 %	3.75%	1.05%	1.75%

### Other fees

You may have to pay other fees when dealing in the shares of the Fund.

### **Additional Information**

- Applications for shares or requests for redemption or exchange of shares ("Orders") can be sent to the Hong Kong Representative, which will endeavour to forward Orders received by 5:00 p.m. (Hong Kong time) on a business day to the Transfer Agent as soon as practicable. Orders received by the Hong Kong Representative by such cut-off time and received by the Transfer Agent in Dublin prior to the close of the regular trading session of the New York Stock Exchange (normally 4:00 p.m. (New York time)) on the same day will be processed on that business day based on the Fund's next-determined net asset value. Investors should note that the distributors may have earlier cut-off times.
- The net asset value per share of the Fund will be made available on each Business Day on our website, [www.janushenderson.com](http://www.janushenderson.com). The aforementioned website has not been reviewed by the Hong Kong Securities and Futures Commission.
- The Hong Kong Representative, Janus Henderson Investors Hong Kong Limited, can be contacted at Suites 706-707, Chater House, 8 Connaught Road Central, Central, Hong Kong, telephone number (852) 3121 7000.

### **Important**

If you are in doubt, you should seek professional advice.

The SFC takes no responsibility for the contents of this statement and makes no representation as to its accuracy or completeness.